Navigation Links
Genmab Announces Updates on Phase III Cancer Studies
Date:5/29/2008

Updates on Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab

COPENHAGEN, Denmark, May 29 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) reports today that the last patient to be included in the planned interim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20(R)) in refractory chronic lymphocytic leukemia (CLL) has now received the last scheduled treatment.

In order to complete the database and allow for assessment of the responses by an independent committee, the final data will now be collected and analysed with the results expected in early August 2008. Pending a positive outcome, a Biologics License application in this indication is expected to be filed before the end of 2008.

Ofatumumab is an investigational drug being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and rheumatoid arthritis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.

Genmab also reported that to date, 132 patients have been dosed in the pivotal Phase III study of zalutumumab (HuMax-EGFr(TM)) to treat head and neck cancer patients considered incurable with standard therapy. As survival is the primary endpoint of this study, a planned interim analysis will take place based on the survival data for patients participating in the study. At present, the Company expects this analysis to occur in 2008, but the exact timing cannot be predicted.

In addition, Genmab announced that based on current recruitment rates, despite broadening the inclusion criteria, the Company does not expect the data to be available this year from the ongoing pivotal Phase III study with zanolimumab (HuMax-CD4(R)) in refractory cutaneous T-cell lymphoma patients.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for un
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
2. Bionomics Achieves US$1 Million Milestone Payment from Genmab
3. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
4. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
5. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
6. BioElectronics Announces Major Clinical Trials
7. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
9. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
10. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
11. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... NEW YORK, Nov. 3, 2010 Coronado Biosciences, ... oncology drug development, announced completion of a series ... gross proceeds to the Company of approximately $21.6 ... from these financings for general corporate purposes, including ...
... Nov. 3, 2010 Telik, Inc. (Nasdaq: TELK ... $0.09 per share, for the third quarter ended September 30, ... $0.11 per share, for the comparable period in 2009. ... costs and expenses were $4.7 million, compared with $6.2 million in ...
Cached Medicine Technology:Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update 2Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update 3Telik Announces Third Quarter 2010 Financial Results 2Telik Announces Third Quarter 2010 Financial Results 3
(Date:4/17/2014)... -- The world is less than 40 years away ... for people and governments, according to a top scientist ... first time in human history, food production will be ... land, water and energy," said Dr. Fred Davies, senior ... "Food issues could become as politically destabilizing by 2050 ...
(Date:4/17/2014)... 17, 2014While 94 per cent of Canadians surveyed said ... newborns for a specific number of genetic conditions, only ... participate in screening that would sequence their newborns, genomes.,Most ... in their first day or two of life in ... their heels and tested for about five to 54 ...
(Date:4/17/2014)... Vice-Chancellor, Professor Patrick Johnston, whose work has transformed cancer ... Fellow of the European Academy of Cancer Sciences., The ... advisory body of highly distinguished oncologists and cancer researchers ... by cancer in Europe. , Professor Johnston, whose leadership ... from the bottom of the UK league table to ...
(Date:4/17/2014)... from LSTM have called for more research to ... in children in sub-Saharan Africa. In a paper ... Professor Russell Stothard, working with colleagues in the ... Reserve University, in Cleveland Ohio, University of Cambridge ... research into the joint burden of HIV/AIDS and ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research ... their annual Founders Dinner for their support of TGen,s ... took place March 28 in Scottsdale. , Catherine Ivy, ... Foundation, received TGen,s John S. McCain Leadership Award, named ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... 2011 Metabolomx, a diagnostic company focused on the ... breath, today announces publication of results from the first ... detect lung cancer and differentiate between types of lung ... the Cleveland Clinic and led by Dr. Peter Mazzone, ...
... patients in a New England Journal of Medicine ... recovered from hip surgery, according to new research co-authored ... findings could immediately change the way such patients are ... strengthen patients weakened by anemia, improving their chances at ...
... been diagnosed with locally-advanced pancreatic cancer in the United ... for these patients whose tumor has grown beyond the ... 20 years, numerous treatment regimens have been evaluated for ... being the current standard approach. However, the median survival ...
... , WEDNESDAY, Dec. 14 (HealthDay News) -- Alcohol ... more of them are using marijuana and don,t believe it,s ... by the U.S. National Institute on Drug Abuse and the ... students in grades eight, 10 and 12 at 400 public ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 14 ... cholesterol levels, may one day also prove useful in combating ... the Journal of Infectious Diseases finds that patients ... were taking a statin, compared with their peers who weren,t ...
... News) -- In the aftermath of a deadly crash in ... Transportation Safety Board is recommending a nationwide ban on drivers, ... emergencies. According to media reports, the board was meeting ... occurred last year in Gray Summit, Mo. The NTSB ...
Cached Medicine News:Health News:Metabolomx test detects lung cancer from breath 2Health News:Metabolomx test detects lung cancer from breath 3Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 2Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 3Health News:RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer 2Health News:Alcohol Use Down, Pot Use Up Among U.S. Teens 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:U.S. Safety Board Urges Nationwide Ban on Drivers' Use of Cellphones 2
This lens gives the appearance of mystery and mayhem behind the blackest of eyes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
Medicine Products: